TRAP-BTC
A small German study giving trastuzumab and pembrolizumab together with standard chemotherapy as the first treatment for HER2-positive bile duct or gallbladder cancer.
Overview
TRAP-BTC (NCT06178445) is a single-arm phase 2 at eight German sites for patients with histologically confirmed cholangiocarcinoma or gallbladder cancer that is HER2-positive and previously untreated, who receive standard gemcitabine and cisplatin with trastuzumab and pembrolizumab. The primary endpoint is objective response rate; 24 patients are planned, the trial opened in April 2024, is active but no longer recruiting, and lists primary completion in December 2026. It tests HER2 antibody plus checkpoint blockade on the chemotherapy backbone in a population in which gallbladder cancer is expected to predominate, ahead of the randomised HERIZON-BTC-302 and DESTINY-BTC01 trials.
Similar pages
not linked directly; found by shared links- TrialEORTC 1607: pembrolizumab with cisplatin and gemcitabine in biliary tract cancer
Shares Gemcitabine + cisplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types).
- TrialEA2197 ivonescimab: ivonescimab with gemcitabine and cisplatin versus standard chemo-immunotherapy in advanced biliary tract cancer
Shares Gemcitabine + cisplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types).
- TrialFirst-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Trastuzumab, Platinum agents, Biliary tract cancer (all types).
- TrialTrastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Trastuzumab, Biliary tract cancer (all types), Monoclonal antibodies.
- TrialPerioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma).
- TrialCTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma).
- TrialSafety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma).
- TrialMulticenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma).